Navigation Links
Panel of melanoma mutations opens door to new treatment possibilities
Date:11/15/2011

SAN FRANCISCO Researchers have developed a new genetic screening tool that will aid in the investigation of possible treatments for patients with melanoma and the unique genetic mutations that may accompany the disease, according to data presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011.

Heinz-Herbert Fiebig, M.D., Ph.D., associate professor of medical oncology at the University of Freiburg in Germany, presented data from 25 patient-derived melanoma models for which he and his colleagues studied relevant genetic mutations and the effect of new targeted and cytotoxic chemotherapeutic agents.

In this study, Fiebig, who is also the president and CEO of Oncotest GmbH Institute for Experimental Oncology, and colleagues collected melanoma samples from 80 patients. They were able to grow 38 of them in nude mice from which 25 permanent models were established. Eight different genetic mutations were determined in these models.

"The most prominent mutations were found in the BRAF oncogene; namely, 16 out of 25 tumors were positive for the mutation," said Fiebig.

About 25 percent of melanoma cases had a mutated NRAS gene. PI3Kalpha mutations were rare, and the screening found no mutations of the KRAS gene, which is a common genetic mutation in other forms of cancer.

The researchers then exposed the melanomas bearing specific mutations in vitro in the clonogenic assay to a variety of cancer treatments including traditional cytotoxic chemotherapy drugs, such as cisplatin, paclitaxel or vincristine, and modern chemotherapeutic drugs that target specific mutations, such as sorafenib and vemurafenib. They hoped to determine which, if any, of these drugs had an effect on the cancer cells and whether that effect was related to the presence or lack of a mutation.

The tests indicated that vemurafenib or PLX-4720 was most effective in melanoma tumor samples with the V600E mutation in the BRAF gene. This finding echoes those of recent clinical studies in humans. In addition, vincristine was found to only be effective in tumor samples that did not have a mutation in the BRAF gene. "Up until now, we were not able to detect other correlations between chemosensitivity against cytotoxic or targeted agents and other mutations," said Fiebig.

In the melanoma models, vemurafenib was 100 times more active in V600E-mutated melanomas compared with those melanomas with no mutations, Fiebig said. However, in the clinic, the majority of patients developed resistance within one year.

"Our melanoma models will allow researchers to investigate and overcome the possible underlying resistance mechanisms for example, by combining vemurafenib with other target-specific agents," Fiebig said. "In addition, other new targeted drugs are being studied in a systematic way."


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Panel asks dairy avoiders: Are you getting enough?
2. Avoiding Dairy Due to Lactose Intolerance is Unnecessary in Most Cases and May Pose Diet and Health Risks, Concludes National Institutes of Health Consensus Development Conference Panel
3. All Global Launches Physician Panels in Russia and Poland
4. Panel questions VBAC bans, advocates expanded delivery options for women
5. Panel Finds Many Women Can Avoid Repeat C-Sections
6. Panel: Properly designed pay-for-performance models can support medical professionalism
7. Panel: FCCs Broadband Plan Will Boost Efforts to Expand Health IT
8. FDA Panel Weighs New Restrictions on Tanning Beds
9. R. Shane Jackson Selected as Panelist for Center for Health Transformation Member Meeting
10. Review Panel Leaves Controversial Lyme Disease Guidelines Unchanged
11. HIA-LI 22nd Annual Business Trade Show & Conference to Feature Healthcare Pavilion and Expert Panel Discussing Healthcare Economics and Politics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... 2017 , ... The Asset Tracking and Temperature monitoring system works in conjunction ... the bar code of the product and lot ID then scanning the HPP basket ... are automatically generated and exception alerts sent out to designated individuals. , "In recognizing ...
(Date:9/25/2017)... ... September 25, 2017 , ... Leonard Bley, MD ... next generation for LASIK in Manhattan with Contoura Vision, the latest WaveLight® topographic-guided ... systems available in the United States to correct nearsightedness and nearsightedness with astigmatism. ...
(Date:9/25/2017)... ... , ... “Renew Refresh Restore Reward”: is a story of struggle and how ... published author, Deborah Freeman, cofounded the Free Spirit Bible Church and currently serves as ... my sister-in-law invited us to come over before the baby had to go back ...
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... “The Majestic ... unicorns—during the great flood. “The Majestic Unicorn” is the creation of published author, Dayna ... or small, came from far and wide to march aboard the cypress ark-vessel. Male ...
(Date:9/25/2017)... Los Angeles, CA (PRWEB) , ... September 25, 2017 , ... ... opening of a full-time office in downtown Los Angeles, to service existing clients in ... the surrounding areas. , “We are seeing an ever-increasing amount of business demand west ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), the company commercializing ... Pharma AG to distribute NuvoAir,s spirometry technology to physicians worldwide. ... platform and Novartis, commitment to address the unmet medical needs ... ... "We are ...
(Date:9/6/2017)... TORONTO , Sept. 6, 2017 /PRNewswire/ ... new knowledge and skills while treating their ... for hands-on experience without involving patients. Simulation ... skills. Clinicians can carry out procedures, refine ... at risk. Integration of new technology, such ...
(Date:9/5/2017)... 5, 2017 Sapheneia and Scannerside received FDA ... DoseCheck is a third-party Vendor neutral CT product that ... allows compliance with current MITA standards. ... DoseCheck solution is specifically designed to provide CT operators, ... radiation doses over a predefined threshold. Scannerside Dose Check ...
Breaking Medicine Technology: